Synonym
YM 16151-1; YM-16151; YM16151.
IUPAC/Chemical Name
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2-(4-((2-hydroxy-3-phenoxypropyl)amino)butoxy)-5-nitrophenyl)-2,6-dimethyl-, dimethyl ester
InChi Key
GQJFGCIETONRNJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H37N3O9/c1-19-26(29(35)39-3)28(27(20(2)32-19)30(36)40-4)24-16-21(33(37)38)12-13-25(24)41-15-9-8-14-31-17-22(34)18-42-23-10-6-5-7-11-23/h5-7,10-13,16,22,28,31-32,34H,8-9,14-15,17-18H2,1-4H3
SMILES Code
CC1=C(C(C(=C(N1)C)C(=O)OC)c2cc(ccc2OCCCCNCC(COc3ccccc3)O)[N+](=O)[O-])C(=O)OC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
583.64
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Uchida W, Shibasaki K, Matsuda Y, Asano M, Takenaka T. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs. J Cardiovasc Pharmacol. 1993 Aug;22(2):247-52. PubMed PMID: 7692165.
2: Uchida W, Shibasaki K, Asano M, Takenaka T. Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. PubMed PMID: 7685438.
3: Uchida W, Shibasaki K, Asano M, Takenaka T. Cardiovascular effects of YM-16151-1 and its optical isomers: a novel calcium entry blocking and beta 1-adrenoceptor blocking agent. Arch Int Pharmacodyn Ther. 1993 Jan-Feb;321:30-40. PubMed PMID: 8100704.
4: Uchida W, Shibasaki K, Asano M. Cardiovascular effects of a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent, YM-16151-4, in anesthetized and conscious dogs. J Cardiovasc Pharmacol. 1992 Jan;19(1):60-8. PubMed PMID: 1375689.
5: Drieu la Rochelle C, Berdeaux A, Richard V, Giudicelli JF. Coronary effects of a combined beta adrenoceptor blocking and calcium antagonist therapy in running dogs. J Cardiovasc Pharmacol. 1991 Dec;18(6):904-10. PubMed PMID: 1725905.
6: Shibasaki K, Uchida W, Matsuda Y, Asano M. Calcium entry blocking, beta 1-adrenoceptor blocking and hypotensive effects of YM-16151-4. Arch Int Pharmacodyn Ther. 1991 Sep-Oct;313:140-50. PubMed PMID: 1687772.
7: Asano M, Uchida W, Shibasaki K, Terai M, Inagaki O, Takenaka T, Matsumoto Y, Fujikura T. Pharmacological profiles of YM-16151-1 and its optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent. J Pharmacol Exp Ther. 1990 Jul;254(1):204-11. PubMed PMID: 1973196.
